Clinical Test Results, Improved Medical Care, and Rejection of Buyout Proposal by Medical Companies - Analyst Notes on AstraZeneca, LifePoint, Insmed, Dendreon and Idenix Pharmaceuticals

Fri May 23, 2014 7:40am EDT

* Reuters is not responsible for the content in this press release.

Clinical Test Results, Improved Medical Care, and Rejection of Buyout Proposal by Medical Companies - Analyst Notes on AstraZeneca, LifePoint, Insmed, Dendreon and Idenix Pharmaceuticals

Editor Note: For more information about this release, please scroll to bottom

PR Newswire

NEW YORK, May 23, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding AstraZeneca PLC (NYSE: AZN), LifePoint Hospitals Inc. (NASDAQ: LPNT), Insmed Incorporated (NASDAQ: INSM), Dendreon Corp. (NASDAQ: DNDN) and Idenix Pharmaceuticals Inc. (NASDAQ: IDIX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2845-100free.

--
AstraZeneca PLC Analyst Notes
On May 19, 2014, AstraZeneca PLC (AstraZeneca) announced the rejection of Pfizer's Final Proposal to acquire the Company, citing that it substantially undervalues the Company. According to the Company, the Final proposal comprised of £24.76 in cash (45%) and 1.747 Pfizer shares (55%) per AstraZeneca share, representing a value of £55.00 per AstraZeneca share. AstraZenec noted that the Board believes Pfizer's proposals fail to recognise the transformation of AstraZeneca and its attractive long term prospects as an independent science-led company. AstraZeneca added that it has excellent momentum in the delivery of its clearly defined strategy, underpinning the Board's confidence in long term revenue targets and profitability. The Company's Chairman Leif Johansson commented on the matter by saying, "We have rejected Pfizer's Final Proposal because it is inadequate and would present significant risks for shareholders, while also having serious consequences for the Company, our employees and the life-sciences sector in the UK, Sweden and the US." The full analyst notes on AstraZeneca are available to download free of charge at:

http://www.analystsreview.com/2845-AZN-23May2014.pdf

--
LifePoint Hospitals Inc. Analyst Notes
On May 20, 2014, LifePoint Hospitals Inc. (LifePoint) announced that it has made a significant progress and advancements in quality and patient safety performance at its hospitals across the country since being selected as a Hospital Engagement Network (HEN) in December 2011. LifePoint stated that the goal set forth by HHS Partnership for Patients initiative for HENs is to achieve a 40% decrease in hospital acquired conditions by December 2014 and the Company is on track of achieving this goal, as it has already succeeded in reducing these conditions by 38% as early as Q1 2014. According to the Company, these efforts are aimed to make hospital care safer, more reliable, and less costly. Chief Medical Officer Russell L. Holman, MD said, "Our success in improving quality and preventing injuries comes from empowering our employees and engaging patients in their care. By involving everyone on the front lines of care, LifePoint has been able to advance a culture of safety in each of our hospitals and provide the best possible care to our communities." The full analyst notes on LifePoint are available to download free of charge at:

http://www.analystsreview.com/2845-LPNT-23May2014.pdf

--
Insmed Incorporated Analyst Notes
On May 20, 2014, Insmed Incorporated (Insmed) announced positive Open Label Data from the Company's phase 2 clinical trial of ARIKAYCE for the treatment of patients with treatment resistant nontuberculous mycobacterial (NTM) lung infection. According to the Company, the results of the additional open label phase showed that 21 of the 68 patients who received once-daily ARIKAYCE added to their standard care treatment for 84 days were culture negative for NTM at Day 168. Insmed noted that these results show a significant increase in culture negative patients compared with the double blind phase of the trial in which 11 out of 44 patients treated with the ARIKAYCE and standard care demonstrated negative cultures by day 84. The Company informed that in the following months, Insmed plans to include the trial results in the discussions with regulatory agencies in the US and Europe to determine next steps for the use of ARIKAYCE in the treatment of NTM lung infections. The full analyst notes on Insmed are available to download free of charge at:

http://www.analystsreview.com/2845-INSM-23May2014.pdf

--
Dendreon Corp. Analyst Notes
On May 20, 2014, Dendreon Corp. (Dendreon) announced the presentation of result from its ProACT and IMPACT studies showing that PROVENGE elicits an elevated immune response associated with an overall survival benefit. "These data further elucidate the mechanism of PROVENGE in the treatment of mCRPC and the important role immunotherapy plays in the prescribing practices of urologists and oncologists, which may improve outcomes for patients," said Andrew S. Sandler, M.D., Executive Vice President and Chief Medical Officer at Dendreon. "The elevated immune response against prostate-specific antigen (PSA) in the ProACT and IMPACT studies is correlated with overall survival, and may point to a useful biomarker of treatment benefit." The full analyst notes on Dendreon are available to download free of charge at:

http://www.analystsreview.com/2845-DNDN-23May2014.pdf

--
Idenix Pharmaceuticals Inc. Analyst Notes
On May 20, 2014, Idenix Pharmaceuticals Inc.'s (Idenix) stock rose by 3.48% to end at $6.25 per share. During the day, the stock fluctuated between $6.58 and $5.99. Moreover, over the past three trading sessions, the Company's stock went up by 9.65% compared to the Nasdaq Composite which increased by 0.68% during the same period. The full analyst notes on Idenix Pharmaceuticals are available to download free of charge at:

http://www.analystsreview.com/2845-IDIX-23May2014.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


SOURCE Analysts Review

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.